This randomized controlled trial has compared the combination of atezolizumab (anti-PDL1 antibody) and bevacizumab (anti VEGF antibody) (n=336) to sorafenib (n=165) in the treatment of advanced HCC. The combination of atezolizumab significantly increased survival (HR 0.58, 95% CI 0.42-0.79; P<0.001) and progression free survival (6.8 months (versus 4.3 months, P<0.001) compared to sorafenib. The main adverse events of the combotherapy were arterial hypertension, proteinuria and immune related adverse events.
(Richard S Finn et al. -New England Journal of Medicine, 14 May 2020)